Comparison of 8-isoprostane and interleukin-8 in induced sputum and exhaled breath condensate from asymptomatic and symptomatic smokers

Respiration

Volumn 78, Issue 2, 2009, Pages 209-216

  Mazur, Witold ^a,b   Stark, Harri ^a   Sovijärvi, Anssi ^b   Myllärniemi, Marjukka ^a   Kinnula, Vuokko L ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

8 Isoprostane; Chronic obstructive pulmonary disease; Exhaled breath condensate; Induced sputum; Interleukin 8

Indexed keywords

8 ISOPROSTANE; INTERLEUKIN 8;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; EXPIRED AIR; FEMALE; HIGH RISK POPULATION; HUMAN; MALE; PRIORITY JOURNAL; SPUTUM ANALYSIS;

ADULT; AGED; BIOLOGICAL MARKERS; BREATH TESTS; DINOPROST; FEMALE; HUMANS; INTERLEUKIN-8; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; SPUTUM;

EID: 68549104362     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000206010     Document Type: Article

References (54)

1. Gan WQ, Man SF, Senthilselvan A, Sin DD: Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59:574-580.
2. Kinnula VL: Focus on antioxidant enzymes and antioxidant strategies in smoking related airway diseases. Thorax 2005;60:693-700.
3. Repine JE, Bast A, Lankhorst I: Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med 1997;156:341-357.
4. de Marco R, Accordini S, Cerveri I, Corsico A, Anto JM, Kunzli N, Janson C, Sunyer J, Jarvis D, Chinn S, et al: Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am J Respir Crit Care Med 2007;175:32-39.
5. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodrig uez-Roisin R, van Weel C, et al: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-555.
6. Barnes PJ, Shapiro SD, Pauwels RA: Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003, 22: 672-688.
7. Hogg JC: Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004;364:709-721.
8. Bucchioni E, Kharitonov SA, Allegra L, Barnes PJ: High levels of interleukin-6 in the exhaled breath condensate of patients with COPD. Respir Med 2003;97:1299-1302.
9. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PM, Celli BR, et al: Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31:416-469.
10. Garey KW, Neuhauser MM, Robbins RA, Danziger LH, Rubinstein I: Markers of inflammation in exhaled breath condensate of young healthy smokers. Chest 2004;125:22-26.
11. Hacievliyagil SS, Gunen H, Mutlu LC, Karabulut AB, Temel I: Association between cytokines in induced sputum and severity of chronic obstructive pulmonary disease. Respir Med 2006;100:846-854.
12. Aaron SD, Angel JB, Lunau M, Wright K, Fex C, Le Saux N, Dales RE: Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:349-355.
13. Gessner C, Scheibe R, Wotzel M, Hammerschmidt S, Kuhn H, Engelmann L, Hoheisel G, Gillissen A, Sack U, Wirtz H: Exhaled breath condensate cytokine patterns in chronic obstructive pulmonary disease. Respir Med 2005;99:1229-1240.
14. Rahman I, MacNee W: Role of oxidants/antioxidants in smoking-induced lung diseases. Free Radic Biol Med 1996;21:669-681.
15. Langen RC, Korn SH, Wouters EF: ROS in the local and systemic pathogenesis of COPD. Free Radic Biol Med 2003;35:226-235.
16. Rytila P, Rehn T, Ilumets H, Rouhos A, Sovijarvi A, Myllarniemi M, Kinnula VL: Increased oxidative stress in asymptomatic current chronic smokers and GOLD stage 0 COPD. Respir Res 2006;7:69.
17. Montuschi P, Ciabattoni G, Paredi P, Pantelidis P, du Bois RM, Kharitonov SA, Barnes PJ: 8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases. Am J Respir Crit Care Med 1998;158:1524-1527.
18. Djukanovic R, Sterk PJ, Fahy JV, Hargreave FE: Standardised methodology of sputum induction and processing. Eur Respir J 2002;37:1s-2s.
19. Horvath I, Hunt J, Barnes PJ, Alving K, Antczak A, Baraldi E, Becher G, van Beurden WJ, Corradi M, Dekhuijzen R, et al: Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J 2005;26:523-548.
20. Vernooy JH, Kucukaycan M, Jacobs JA, Chavannes NH, Buurman WA, Dentener MA, Wouters EF: Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med 2002;166:1218-1224.
21. Carpagnano GE, Kharitonov SA, Foschino-Barbaro MP, Resta O, Gramiccioni E, Barnes PJ: Increased inflammatory markers in the exhaled breath condensate of cigarette smokers. Eur Respir J 2003;21:589-593.
22. van Beurden WJ, van den Bosch MJ, Janssen WC, Smeenk FW, Dekhuijzen PN, Harff GA: Fluorimetric analysis of hydrogen peroxide with automated measurement. Clin Lab 2003;49:637-643.
23. Corradi M, Pignatti P, Manini P, Andreoli R, Goldoni M, Poppa M, Moscato G, Balbi B, Mutti A: Comparison between exhaled and sputum oxidative stress biomarkers in chronic airway inflammation. Eur Respir J 2004;24:1011-1017.
24. Profita M, Giorgi RD, Sala A, Bonanno A, Riccobono L, Mirabella F, Gjomarkaj M, Bonsignore G, Bousquet J, Vignola AM: Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients. Allergy 2005; 60: 1361-1369.
25. Ko FW, Lau CY, Leung TF, Wong GW, Lam CW, Hui DS: Exhaled breath condensate levels of 8-isoprostane, growth related oncogene α and monocyte chemoattractant protein-1 in patients with chronic obstructive pulmonary disease. Respir Med 2006;100: 630-638.
26. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA: Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000;55:114-120.
27. Biernacki WA, Kharitonov SA, Barnes PJ: Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD. Thorax 2003; 58: 294-298.
28. Tsoumakidou M, Tzanakis N, Chrysofakis G, Siafakas NM: Nitrosative stress, heme oxygenase-1 expression and airway inflammation during severe exacerbations of COPD. Chest 2005;127:1911-1918.
29. Jones PW, Quirk FH, Baveystock CM: The St George's Respiratory Questionnaire. Respir Med 1991;85(suppl B):25-31; discussion 33-27.
30. Kelly MM, Keatings V, Leigh R, Peterson C, Shute J, Venge P, Djukanovic R: Analysis of fluid-phase mediators. Eur Respir J 2002;37: 24s-39s.
31. Rytila P, Plataki M, Bucchieri F, Uddin M, Nong G, Kinnula VL, Djukanovic R: Airway neutrophilia in COPD is not associated with increased neutrophil survival. Eur Respir J 2006;28:1163-1169.
32. Kinnula VL, Ilumets H, Myllarniemi M, Sovijarvi A, Rytila P: 8-Isoprostane as a marker of oxidative stress in nonsymptomatic cigarette smokers and COPD. Eur Respir J 2007; 29:51-55.
33. Barnes PJ, Chowdhury B, Kharitonov SA, Magnussen H, Page CP, Postma D, Saetta M: Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;174:6-14.
34. Wood LG, Garg ML, Simpson JL, Mori TA, Croft KD, Wark PA, Gibson PG: Induced sputum 8-isoprostane concentrations in inflammatory airway diseases. Am J Respir Crit Care Med 2005;171:426-430.
35. Simpson JL, Wood LG, Gibson PG: Inflammatory mediators in exhaled breath, induced sputum and saliva. Clin Exp Allergy 2005;35:1180-1185.
36. Louhelainen N, Rytila P, Obase Y, Makela M, Haahtela T, Kinnula VL, Pelkonen A: The value of sputum 8-isoprostane in detecting oxidative stress in mild asthma. J Asthma 2008;45:149-154.
37. Makris D, Paraskakis E, Korakas P, Karagiannakis E, Sourvinos G, Siafakas NM, Tzanakis N: Exhaled breath condensate 8-isoprostane, clinical parameters, radiological indices and airway inflammation in COPD. Respiration 2008;75:138-144.
38. Kostikas K, Papatheodorou G, Psathakis K, Panagou P, Loukides S: Oxidative stress in expired breath condensate of patients with COPD. Chest 2003;124:1373-1380.
39. Montuschi P, Collins J V, Ciabattoni G, Lazzeri N, Corradi M, Kharitonov SA, Barnes PJ: Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med 2000;162:1175-1177.
40. Van Hoydonck PG, Wuyts WA, Vanaudenaerde BM, Schouten EG, Dupont LJ, Temme EH: Quantitative analysis of 8-isoprostane and hydrogen peroxide in exhaled breath condensate. Eur Respir J 2004;23:189-192.
41. Rosias PP, Robroeks CM, Niemarkt HJ, Kester AD, Vernooy JH, Suykerbuyk J, Teunissen J, Heynens J, Hendriks HJ, Jobsis Q, et al: Breath condenser coatings affect measurement of biomarkers in exhaled breath condensate. Eur Respir J 2006;28:1036-1041.
42. Masubuchi T, Koyama S, Sato E, Takamizawa A, Kubo K, Sekiguchi M, Nagai S, Izumi T: Smoke extract stimulates lung epithelial cells to release neutrophil and monocyte chemotactic activity. Am J Pathol 1998;153: 1903-1912.
43. Mio T, Romberger DJ, Thompson AB, Robbins RA, Heires A, Rennard SI: Cigarette smoke induces interleukin-8 release from human bronchial epit helia l cells. Am J Respir Crit Care Med 1997;155:1770-1776.
44. Schulz C, WolfK, Harth M, Krat zel K, Kunz-Schughart L, Pfeifer M: Expression and release of interleukin-8 by human bronchial epithelial cells from patients with chronic obstructive pulmonary disease, smokers, and never-smokers. Respiration 2003; 70: 254-261.
45. Yamamoto C, Yoneda T, Yoshikawa M, Fu A, Tokuyama T, Tsukaguchi K, Narita N: Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest 1997;112: 505-510.
46. Keatings VM, Collins PD, Scott DM, Barnes PJ: Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996;153:530-534.
47. Beeh KM, Kornmann O, Buhl R, Culpitt SV, Giembycz MA, Barnes PJ: Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. Chest 2003;123:1240-1247.
48. Kim JS, Okamoto K, Rubin BK: Pulmonary function is negatively correlated with sputum inf lammatory markers and cough clearability in subjects with cystic fibrosis but not those with chronic bronchitis. Chest 2006;129:1148-1154.
49. Carpagnano GE, Resta O, Foschino-Barbaro MP, Spanevello A, Stefano A, Di Gioia G, Serviddio G, Gramiccioni E: Exhaled Interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate (SCMC-Lys). Eur J Pharmacol 2004;505:169-175.
50. Drost EM, Skwarski KM, Sauleda J, Soler N, Roca J, Agusti A, MacNee W: Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax 2005;60:293-300.
51. Sack U, Scheibe R, Wotzel M, Hammerschmidt S, Kuhn H, Emmrich F, Hoheisel G, Wirtz H, Gessner C: Multiplex analysis of cytokines in exhaled breath condensate. Cytometry A 2006;69:169-172.
52. Willemse BW, ten Hacken NH, Rutgers B, Postma DS, Timens W: Association of current smoking with airway inflammation in chronic obstructive pulmonary disease and asymptomatic smokers. Respir Res 2005; 6: 38.
53. Sapey E, Bayley D, Ahmad A, Newbold P, Snell N, Stockley RA: Inter-relationships between inflammatory markers in patients with stable COPD with bronchitis: intra-patient and inter-patient variability. Thorax 2008;63:493-499.
54. Chavannes NH, Vernooy JH, Schermer TR, Jacobs JA, Dentener MA, van Weel C, van Schayck OC, Wouters EF: Patterns of inflammation and the use of reversibility testing in smokers with airway complaints. BMC Pulm Med 2006;6:11.